Treatment of myelodysplastic syndrome with cyclosporin A

International Journal of Hematology

Volumn 85, Issue 1, 2007, Pages 11-17

  Chen, Shuchang ^a,e   Jiang, Bin ^b   Da, Wanming ^c   Gong, Ming ^d   Guan, Mei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d Sino Japan Friendship Hospital   (China)

^e PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Cyclosporin A (CsA); Immunosuppression; Myelodysplastic syndrome (MDS)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLOSPORIN A; SANDIMUNN NEORAL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; BONE MARROW HYPERPLASIA; BONE MARROW HYPOPLASIA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GINGIVA HYPERPLASIA; HAIR DISEASE; HUMAN; HYPERGLYCERIDEMIA; HYPERKALEMIA; HYPERMETABOLISM; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTION; KIDNEY DYSFUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PARESTHESIA; PROSPECTIVE STUDY; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REMISSION; SIDE EFFECT; STOMACH PAIN; SURVIVAL TIME; TREATMENT OUTCOME; TREMOR; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANEMIA, SIDEROBLASTIC; BONE MARROW; CHILD; CYCLOSPORINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846692197     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.A10513     Document Type: Article

References (27)

1. Smith MA, Smith JG. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res. 1991;15:597-601.
2. Sugawara T, Endo K, Shishido T, et al. T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes. Am J Hematol. 1992;41:304-305.
3. Baumann I, Scheid C, Koref MS, Swindell R, Stern P, Testa NG. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp Hematol. 2002;30:1405-1411.
4. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol. 1998;102:1314-1322.
5. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
6. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol. 2001;29:1270-1277.
7. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res. 2001;25:1075-1083.
8. Barrett AJ, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia; distinct entities or diseases linked by a common pathopysiology? Semin Hematol. 2000;37:15-29.
9. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 1992;6:1268-1272.
10. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049-2054.
11. Preudhomme C, Vachee A, Morschauser F, Henic N, Cosson A, Fenaus P. Immunoglobulin and T-cell receptor deltagene rearrangements are rarely found in myelodysplastic syndromes in chronic phase. Leuk Res. 1994;18:365-371.
12. Wainscoat JS, Fey MF, Pilkington S, Summers C, Oscier DG. Absence of immunoglobulin and T-cell receptor gene rearrangements in myelodysplastic syndromes and acute nonlymphocytic leukemias. Amer J Hematol. 1988;28:95-97.
13. Shimamoto T, Ohyashiki K. Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma. 2003;44:593-604.
14. Sloand EM, Kim S, Young NS, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood. 2002;100:4427-4432.
15. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing Ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98:3058-3065.
16. Mundle SD, Reza S, Ali A, et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett. 1999;140(1-2):201-207.
17. Mundle SD, Ali A, Cartlidge JD, et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol. 1999;60:36-47.
18. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103:176-188.
19. Selleri L, Maciejewski JP, Rotoli B, et al. Effects of cyclosporine on hematopoietic and immune function in patients with hypoplastic myelodysplasia in vitro and in vivo studies. Cancer. 2002;95:1911-1922.
20. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100:304-309.
21. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79:1548-1551.
22. Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res. 2003;27:783-788.
23. Chen SC, Zhu H, Lu R, et al. Origin and progress of myelodysplastic syndrome with hypoplasia. Chin J Int Med. 1999;38:370-372.
24. Jia ZL, Gong WL, Mei W, et al. The effect of CsA on the CFU-E and CFU-Gm in patients of AA and MDS. Chin J Int Med. 2001;40:47-48.
25. Young NS. The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood. 1992;79:1385-1392.
26. Reymond JP, Steimer JL, Niederberger W. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm. 1988;16:331-353.
27. Ogata M, Ohtsuka E, Imamura T, et al. Response to cycloposine therapy in patients with myelodysplastic syndrome: a clonical study of 12 cases and literature review. Int J Hematology. 2004;80:35-42.